# The mechanism of Vicenin-2 in ameliorating skin photoaging: involvement of m6A-modified macrophage polarization

**Authors:** Yan Zhou, Wenlong Shuai, Xinyi Peng, Ruishan Li, Meng Chen, Bowen Tan, Yunzhu Mu, Xi Duan

PMC · DOI: 10.3389/fphar.2026.1778993 · Frontiers in Pharmacology · 2026-02-19

## TL;DR

This study explores how Vicenin-2, a natural flavonoid, reduces skin photoaging by shifting macrophages to an anti-inflammatory state through m6A RNA modifications.

## Contribution

The study reveals a novel mechanism by which Vicenin-2 modulates macrophage polarization via m6A modification and NF-κB signaling in photoaging.

## Key findings

- Vicenin-2 reduces skin damage and improves hydration by promoting M2 macrophage polarization.
- Vicenin-2 upregulates KIAA1429, enhancing m6A RNA methylation and inhibiting NF-κB activation.
- Topical Vicenin-2 treatment shows potential as a new intervention for photoaging.

## Abstract

Skin photoaging is primarily induced by ultraviolet radiation and is closely associated with chronic inflammation and degradation of the extracellular matrix, with an imbalance in macrophage polarization (elevated M1/M2 ratio) being a key factor.

This study first conducted single-cell sequencing analysis to investigate the correlation between macrophage subtypes and photoaging. At the same time, we investigated the effects and mechanisms of the natural flavonoid Vicenin-2 on photoaging through both in vivo and in vitro experiments. In vitro, Vicenin-2 was applied to LPS-induced RAW264.7 macrophages; in vivo, a mouse model of photoaging was established using UVA/UVB irradiation, followed by topical treatment with different concentrations of Vicenin-2 cream.

It was found that in the photodamage model, the infiltration of pro-inflammatory M1 macrophages significantly increased, and the key regulatory factor KIAA1429 was positively correlated with the level of anti-inflammatory M2 macrophages. The results showed that Vicenin-2 significantly alleviated skin damage, improved hydration and collagen organization, and promoted the shift of macrophages from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype. Mechanistically, Vicenin-2 upregulated the m6A modification regulator KIAA1429, enhanced overall m6A RNA methylation, and inhibited NF-κB pathway activation by suppressing p65 phosphorylation.

The findings indicate that Vicenin-2 may mitigate skin photoaging by modulating macrophage polarization toward the M2 phenotype through m6A-dependent regulation of the NF-κB signaling pathway, supporting its potential as a novel topical agent for photoaging intervention.

## Linked entities

- **Genes:** VIRMA (vir like m6A methyltransferase associated) [NCBI Gene 25962], RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970]
- **Chemicals:** Vicenin-2 (PubChem CID 442664)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Mettl14 (methyltransferase 14, N6-adenosine-methyltransferase subunit) [NCBI Gene 210529] {aka G430022H21Rik, mKIAA1627}, WTAP (WT1 associated protein) [NCBI Gene 9589] {aka Mum2}, Mmp13 (matrix metallopeptidase 13) [NCBI Gene 17386] {aka Clg, MMP-13, Mmp1}, Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, FTO (FTO alpha-ketoglutarate dependent dioxygenase) [NCBI Gene 79068] {aka ALKBH9, BMIQ14, GDFD, IFEX9}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, Il1 (interleukin 1 complex) [NCBI Gene 111343] {aka Il-1}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, VIRMA (vir like m6A methyltransferase associated) [NCBI Gene 25962] {aka KIAA1429, MSTP054, fSAP121}, Virma (vir like m6A methyltransferase associated) [NCBI Gene 66185] {aka 1110037F02Rik, 4930422M05Rik, Kiaa1429, mKIAA1429}, Rela (Rela proto-oncogene, NFKB subunit) [NCBI Gene 19697] {aka p65, p65 NF-kappa B, p65 NFkB}, Umod (uromodulin) [NCBI Gene 22242] {aka THP, Urehd1, urehr4}, Mettl3 (methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit) [NCBI Gene 56335] {aka 2310024F18Rik, M6A, Spo8}, Wtap (WT1 associating protein) [NCBI Gene 60532] {aka 2810408K05Rik, 9430038B09Rik}, Jun (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 16476] {aka AP-1, Junc, c-jun}, METTL14 (methyltransferase 14, N6-adenosine-methyltransferase non-catalytic subunit) [NCBI Gene 57721] {aka hMETTL14}, Tnfaip3 (tumor necrosis factor, alpha-induced protein 3) [NCBI Gene 21929] {aka A20, Tnfip3}, Cd86 (CD86 antigen) [NCBI Gene 12524] {aka B7, B7-2, B7.2, B70, CLS1, Cd28l2}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Tnfsf9 (tumor necrosis factor (ligand) superfamily, member 9) [NCBI Gene 21950] {aka 4-1BB-L, 4-1BBL, Cd137l, Ly63l}, Serpina1b (serine (or cysteine) preptidase inhibitor, clade A, member 1B) [NCBI Gene 20701] {aka D12Ucla2, Dom2, PI2, Spi1-2}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, METTL3 (methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit) [NCBI Gene 56339] {aka IME4, M6A, MT-A70, Spo8, hMETTL3}, Nos2 (nitric oxide synthase 2, inducible) [NCBI Gene 18126] {aka MAC-NOS, NOS-II, Nos-2, Nos2a, i-NOS, iNOS}, Cd68 (CD68 antigen) [NCBI Gene 12514] {aka Lamp4, Scard1, gp110}, Lrp4 (low density lipoprotein receptor-related protein 4) [NCBI Gene 228357] {aka 6430526J12Rik, D230026E03, Megf7, mdig}, Mmp3 (matrix metallopeptidase 3) [NCBI Gene 17392] {aka EMS-2, MMP-3, SL-1, SLN-1, SLN1, STR-1}, Arg1 (arginase, liver) [NCBI Gene 11846] {aka AI, Arg-1, PGIF}, Mapk1 (mitogen-activated protein kinase 1) [NCBI Gene 26413] {aka 9030612K14Rik, ERK, Erk2, MAPK2, PRKM2, Prkm1}
- **Diseases:** allergic reactions (MESH:D004342), non-melanoma skin cancer (MESH:D012878), dryness (MESH:D014987), laxity (MESH:D007593), chronic (MESH:D002908), squamous cell carcinoma (MESH:D002294), basal cell carcinoma (MESH:D002280), pigmentary disorders (MESH:C535508), erythema (MESH:D004890), dislocation (MESH:D004204), skin injury (MESH:D000069836), hypopigmentation (MESH:D017496), skin damage (MESH:D012871), hyperpigmentation (MESH:D017495), chronic inflammation (MESH:D007249), dermatological disorders (MESH:D000168), toxicity (MESH:D064420), sunburn (MESH:D013471), actinic keratosis (MESH:D055623), macrophage (MESH:D055501), tumor (MESH:D009369)
- **Chemicals:** retinoids (MESH:D012176), Trizol (MESH:C411644), paraformaldehyde (MESH:C003043), LPS (MESH:D008070), CPDs (MESH:D011740), BCA (MESH:C047117), petroleum jelly (MESH:D010577), CO2 (MESH:D002245), citrate (MESH:D019343), m6A (MESH:C005955), water (MESH:D014867), AP (MESH:D000667), reactive oxygen species (MESH:D017382), monoglyceride (MESH:D050178), ice (MESH:D007053), DAPI (MESH:C007293), Flavonoids (MESH:D005419), formaldehyde (MESH:D005557), ethanol (MESH:D000431), SDS (MESH:D012967), PVDF (MESH:C024865), eosin (MESH:D004801), hematoxylin (MESH:D006416), glycerol (MESH:D005990), penicillin (MESH:D010406), Vicenin-2 (MESH:C530449), H&amp;E (MESH:D006371), paraffin (MESH:D010232), N6-methyladenosine (MESH:C010223), 6,8-di-C-glucoside (-), ozone (MESH:D010126), oil (MESH:D009821), streptomycin (MESH:D013307), Triton X-100 (MESH:D017830), Picrosirius Red (MESH:C009798), reactive nitrogen species (MESH:D026361), EVG (MESH:C509700)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Mutations:** C-80  C, C-23  C
- **Cell lines:** RAW264.7 — Mus musculus (Mouse), Mouse leukemia, Cancer cell line (CVCL_0493), NSMC2025- — Homo sapiens (Human), Finite cell line (CVCL_V825), BALB/c — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0184)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12960571/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12960571/full.md

## References

58 references — full list in the complete paper: https://tomesphere.com/paper/PMC12960571/full.md

---
Source: https://tomesphere.com/paper/PMC12960571